Cancer Ongoing 2021 North Shore NSW

AdvanTIG – BGB-A317-A1217-302

The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.

Trial overview

Lung cancer
AdvanTIG – BGB-A317-A1217-302
A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
Eligibility criteria

Stage IV Non-Small Cell Lung Cancer with high PDL1 and no driver mutations

Study details

Treatment is Tizlelizumab with an Anti-TIGIT antibody vs Pembrolizumab with placebo vs Tizlelizumab with placebo at a ratio of 5:5:1While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


North Shore NSW